Abstract:

Objective To evaluate the early safety of HBcAb positive donor used on pediatric living donor liver transplant recipients. Methods We collected and registered the data of 86 pediatric living donor liver transplant recipients from July 2010 to December 2013 in Tianjin First Center Hospital. The patients were divided into HBcAb+ group and HBcAb- group according to donors' serumtest of HBcAb. The preoperative state，operation time，ICU stay time and postoperative liver function of both group were compared. Results 5 cases died among 86 pediatric living donor liver transplant recipients，and total mortality was 5.81% with 9.37% and 3.70% for HBcAb+ groupand HBcAb- group respectively without statistical difference.All pediatric recipients had no hepatitis B occurred perioperatively and there were no statistical differences of twogroups in average age and weight of recipients，preoperative PELD scores，average age and weight of donors，weight of liver graft，operation time（547.44±71.93 min vs. 546.76±95.67 min），ICU stay（119.27±50.61 hr vs. 126.61±70.78 hr）， serum value of total bilirubin，direct bilirubin，glutamic-pyruvic transaminase，glutamic-oxalacetic transaminase and international normalized ratio of 1 and 2 days before operation and post-operative day 1，3，7，14，28. （P ＞ 0.05）. Conclusion HBcAb positive liver grafts，on the basis of accurate assessment and appropriatemeasurement applied to preventhepatitisB recurrence，were safe for pediatric patients perioperativelyat least.